These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20922784)

  • 1. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
    Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
    Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
    Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
    Campbell MT; Millikan RE; Altinmakas E; Xiao L; Wen SJ; Siefker-Radtke AO; Aparicio A; Corn PG; Tannir NM
    Clin Genitourin Cancer; 2015 Jun; 13(3):218-24. PubMed ID: 25465491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
    Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
    Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
    J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
    Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
    BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
    Atkins MB; Gravis G; Drosik K; Demkow T; Tomczak P; Wong SS; Michaelson MD; Choueiri TK; Wu B; Navale L; Warner D; Ravaud A
    J Clin Oncol; 2015 Oct; 33(30):3431-8. PubMed ID: 26304872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes G; Wilding G; Schwartz LH; Hariharan S; Kempin S; Fayyad R; Figlin RA
    Clin Genitourin Cancer; 2009 Jan; 7(1):28-33. PubMed ID: 19213665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
    Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
    Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.
    Schmidinger M; Szczylik C; Sternberg CN; Kania M; Kelly CS; Decker R; Hamid O; Faelker T; Escudier B
    Am J Clin Oncol; 2012 Oct; 35(5):493-7. PubMed ID: 21654314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
    Tan HS; Li H; Hong YW; Toh CK; Wong A; Lopes G; Tay MH; Chan A; Yao X; Tang T; Ng QS; Kanesvaran R; Chau NM; Tan MH
    Clin Genitourin Cancer; 2015 Aug; 13(4):e285-e295. PubMed ID: 25541325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ; Tian J; Chen X; Wang D; Li CL
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
    Aglietta M; Barone C; Sawyer MB; Moore MJ; Miller WH; Bagalà C; Colombi F; Cagnazzo C; Gioeni L; Wang E; Huang B; Fly KD; Leone F
    Ann Oncol; 2014 Sep; 25(9):1750-1755. PubMed ID: 24907635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.